冷凝
结晶
材料科学
化学
组合化学
有机化学
物理
热力学
作者
Jie Xu,Cheol K. Chung,Andrew McClory,Kyle A. Mack,Michael E. Dalziel,Alec Fettes,Kyle Clagg,Ngiap‐Kie Lim,Georg Wuitschik,Christian Jenny,Laure Finet,Michael Kammerer,Haiming Zhang,Rémy Angelaud,Francis Gosselin
标识
DOI:10.1021/acs.oprd.1c00263
摘要
GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2– breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C–N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet–Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.
科研通智能强力驱动
Strongly Powered by AbleSci AI